Status:
UNKNOWN
Median Effective Dose of Remifentanil for the Prevention of Pain Caused by the Injection of Rocuronium
Lead Sponsor:
Yangzhou University
Conditions:
Rocuronium
Injection Pain
Eligibility:
All Genders
18-80 years
Phase:
NA
Brief Summary
As a medium-and long-term non-depolarizing muscle relaxant, rocuronium has the advantages of quick effect, no histamine release and accumulation and no obvious cardiovascular adverse reactions, so it ...
Eligibility Criteria
Inclusion
- Ages ranged from 18 to 80.
- ASA # or # level.
Exclusion
- Allergy or contraindication to remifentanil or rocuronium; required for Central venipuncture catheterization;
- Abnormal liver or kidney function;
- Heavy drinking and long-term use of sedatives, analgesics or anti-anxiety drugs;
- Hearing and language impairment;
- Peripheral vascular disease;
- Severe cardiovascular disease or neurological disorders;
- Failure of one-time peripheral venipuncture;
- Infection of hand or wrist skin.
Key Trial Info
Start Date :
December 18 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
March 30 2022
Estimated Enrollment :
70 Patients enrolled
Trial Details
Trial ID
NCT05217238
Start Date
December 18 2021
End Date
March 30 2022
Last Update
February 1 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
the Affiliated Hospital of Yangzhou University
Yangzhou, Jiangsu, China, 225000